Acute Effects of Sodium GlucOse Co-Transporter 2 (SGLT2) Inhibition on Hepatic Glucose and Energy Metabolism
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Dec 2020 Results investigating the impact of a single dose of dapagliflozin (D) or placebo (P) on hepatic glycogenolysis, hepatocellular lipid (HCL) content and mitochondrial activity (kATP), published in the Diabetes Care.
- 25 Sep 2020 Results investigating the impact of a single dose of dapagliflozin (D) or placebo (P) on hepatic glycogenolysis, lipid content (HCL) and mitochondrial activity ( k ATP) presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 26 Sep 2016 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.